Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | PLA2G7 | Q13093 | 8/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585786 | 0.79 | SLC22A12 (0.41) | SLC22A12PLA2G7SCN9AKCNQ3KCNQ2 | |
| SCHEMBL586070 | 0.77 | SLC22A12 (0.42) | SLC22A12PLA2G7SCN9AKCNQ3KCNQ2 | |
| SCHEMBL585385 | 0.76 | SLC22A12 (0.44) | SLC22A12PLA2G7SCN9AKCNQ3KCNQ2 | |
| SCHEMBL585580 | 0.74 | SLC22A12 (0.42) | SLC22A12PLA2G7SCN9AKCNQ3KCNQ2 | |
| SCHEMBL585430 | 0.74 | SLC22A12 (0.41) | SLC22A12PLA2G7SCN9ATACR1KCNQ3 | |
| SCHEMBL883842 | 0.71 | SLC22A12 (0.46) | SLC22A12PLA2G7SCN9APTGDR2 | |
| SCHEMBL585875 | 0.71 | SLC22A12 (0.45) | SLC22A12PLA2G7SCN9APTGDR2 | |
| SCHEMBL585259 | 0.69 | KCNQ3 (0.41) | TACR1KCNQ3KCNQ2PTGDR2 | |
| SCHEMBL585990 | 0.66 | PTGDR2 (0.44) | KCNQ3KCNQ2PTGDR2 | |
| SCHEMBL585444 | 0.66 | RORC (0.44) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963259-B1 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |